Is Thailand PGT-M Monogenic Disease Screening Reliable? Reproductive Doctors Explain Accuracy and Risks

Article Meta Information

Opening: Doctor's Decision Logic

Doctor's Decision Logic: When to Recommend Thailand PGT-M to Patients

In reproductive genetics clinics, when encountering patients carrying clear pathogenic gene mutations, PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) is one of the standard options to block the transmission of genetic diseases. One of the most common questions patients ask is: "Is Thailand PGT-M monogenic disease screening reliable?" This question cannot be simply answered with "reliable" or "unreliable." As a reproductive doctor, a comprehensive evaluation must be made from multiple dimensions, including technical principles, clinical applications, differences in national regulations, and institutional selection.

The core goal of PGT-M is to screen embryos that do not carry specific pathogenic genes before implantation, thereby preventing the transmission of genetic diseases to the next generation. In recent years, Thailand has become a choice for some patients, mainly due to higher process efficiency, the possibility of selective transfer, and relatively competitive costs. However, the reliability of the technology needs to be broken down and analyzed at different levels.

A Direct Answer to the Question

Direct Answer: Is Thailand PGT-M Reliable?

Thailand PGT-M monogenic disease screening is reliable in technically standardized institutions, but a series of prerequisites must be met.

From the perspective of the detection technology itself, the mainstream global PGT-M platforms (Next-Generation Sequencing NGS, Fluorescent Quantitative PCR, SNP Arrays) are all used in top-tier Thai reproductive centers, with no essential difference from leading centers in Europe, America, or China. Clinical data shows that, provided a standardized family pre-test is completed and a validated testing protocol is used, the accuracy of PGT-M in some Thai institutions can reach 95%–99%.

B Why This Question Arises

Why Patients Have Doubts About Thailand PGT-M

Behind the question "Is Thailand PGT-M reliable?" there are four practical reasons:

• Strict domestic PGT-M access: In China, PGT-M requires strict medical indications, and waiting times for cycles in some centers are long (3–6 months), leading patients to seek faster pathways.
• Prominent information asymmetry: Thai medical tourism promotions often highlight "high success rates" and "advanced technology," but it is difficult for patients to distinguish which institutions truly have the technical capability and which are merely marketing hype.
• Technical details are oversimplified: Monogenic disease screening involves complex concepts like family pre-testing, embryonic mosaicism, and allele drop-out (ADO). Some promotional materials deliberately avoid these technical limitations, leaving patients unprepared when problems arise later.
• Outsourcing of testing exists: Some small Thai institutions send embryo biopsy samples to third-party laboratories for testing, increasing intermediate steps and raising quality control risks. Patients are often unaware of where their samples are ultimately analyzed.

C The Doctor's Perspective

The Doctor's Perspective: Six Dimensions for Evaluating Thailand PGT-M Reliability

From a clinical reproductive doctor's professional viewpoint, evaluating the reliability of a PGT-M service requires verifying the following elements one by one:

1. Is the family pre-test completed? PGT-M must be based on confirming the pathogenic site in the proband or both partners, designing a personalized testing protocol. Institutions that proceed directly to the cycle without completing the family pre-test lack reliability, regardless of the country.
2. Experience level of the biopsy team: Embryo biopsy is a critical operational step in PGT-M. The training background of biopsy personnel, annual number of procedures, and embryo damage rate directly affect the test results and the subsequent developmental potential of the embryo.
3. Independence and certification of the testing platform: Reliable institutions have their own genetics laboratory or partner with well-known CAP/CLIA certified laboratories (e.g., Juno Genetics, Genomic Prediction). Sending samples to untraceable small laboratories introduces uncontrollable risks.
4. Is genetic counseling provided throughout the process? From counseling before the family pre-test, to interpreting test results, to recommendations for prenatal diagnosis after transfer, qualified genetic counselors must be involved. Superficial counseling cannot help patients make correct decisions.
5. Quality control information in the result report: A standard PGT-M report includes quality control parameters such as the testing platform, coverage region, sequencing depth, ADO risk indication, and mosaicism threshold. Reports that are too simple often indicate hidden technical details.
6. Are there clear guidelines for prenatal diagnosis? No PGT-M result can replace prenatal diagnosis. Reliable institutions will clearly recommend amniocentesis for verification after pregnancy in their reports, rather than promising "100% accuracy."

E Differences Between Countries

Differences Between Countries: Comparison of PGT-M in Thailand, China, and the USA

Understanding the characteristics of PGT-M in different countries helps patients choose based on their own circumstances. The following comparison is made from six key dimensions:

Comparison Dimension	Thailand	China	USA
Technology Platform	Primarily NGS, some institutions collaborate with overseas labs	Primarily NGS and PCR, top-tier hospitals have in-house platforms	Most cutting-edge technology, diverse platforms (NGS+SNP+Long-read sequencing)
Regulations & Oversight	Relatively relaxed, selective transfer possible, but institutional levels vary	Strict, must meet medical indications, clear ethical approval process	Varies by state, mostly relaxed, but laboratory certification system is strict
Variation in Institutional Level	Significant gap between top-tier and average institutions, high selection cost	Stable level in top-tier hospitals, but uneven resource distribution	Generally high level, but differences exist between clinics
Cycle Waiting Time	1–2 months (including genetic counseling and family pre-test)	3–6 months (queue + approval + cycle)	1–2 months
Cost Range (CNY)	80,000 – 150,000 (including PGT-M testing)	50,000 – 100,000 (excluding ovulation induction medication)	200,000 – 350,000 (30,000 – 50,000 USD)
Genetic Counseling Provision	Adequate in some institutions, superficial in others	Standard in top-tier hospitals, but counseling resources are limited	Standard, high level of professionalism, mature multidisciplinary collaboration

The positioning of Thailand PGT-M can be summarized as "a balanced choice between efficiency and cost-effectiveness," but only if a technically standardized institution is selected. The advantage in China lies in strict regulation and standardized processes, but waiting times are longer. The advantage in the USA lies in cutting-edge technology and multidisciplinary collaboration, but the cost barrier is the highest.

G The Most Easily Overlooked Details

The Most Easily Overlooked Details: Five Limitations of PGT-M Technology Itself

When discussing "Is Thailand PGT-M reliable," the following technical details are often overlooked, yet they are crucial for determining the reliability of the results:

Embryonic Mosaicism

During early embryonic division, different cell lines may have inconsistent genotypes. Biopsy of 5–10 trophectoderm cells may not fully represent the genetic status of the entire embryo. The higher the proportion of mosaicism, the greater the risk of misdiagnosis. Standard reports will indicate the mosaicism ratio and interpretation recommendations.

Allele Drop-Out (ADO)

During PCR amplification, one allele may fail to amplify, causing a heterozygous mutation to be misdiagnosed as a homozygous mutation. Standard laboratories use SNP polymorphic markers for quality control to reduce the risk of ADO. Patients should proactively ask about the laboratory's ADO control strategy.

Mutation Type Coverage of the Testing Platform

NGS has high accuracy for point mutations and known deletions/duplications, but for types like dynamic mutations (e.g., Huntington's disease), methylation abnormalities, and mitochondrial mutations, specialized testing protocols are required. Not all Thai institutions can handle complex mutation types.

Potential Impact of Biopsy on Embryo Developmental Potential

Although the current mainstream view is that experienced biopsy operations have a manageable impact on blastocyst implantation rates, some studies still show that the implantation rate of biopsied embryos is slightly lower than that of non-biopsied embryos. For patients with a low number of embryos, this impact needs to be considered in decision-making.

Uncertainty and Gray Areas in Results

PGT-M results are not always a simple dichotomy of "normal" or "abnormal." Some embryos may yield conclusions like "uncertain," "mosaic," or "needs re-testing." Patients need to be aware of these possibilities in advance to avoid being caught in a decision dilemma after receiving results.

H Common Pitfalls

Common Pitfalls: Five Common Mistakes When Choosing a Thailand PGT-M Institution

Based on clinical observations, patients undergoing PGT-M in Thailand most commonly make the following five decision errors:

I Actual Process

Actual Process: Standard Pathway for Thailand PGT-M Monogenic Disease Screening

A standard, complete Thailand PGT-M process should include the following seven stages. Each stage has clear clinical goals and quality control points:

1. Genetic Counseling and Family Pre-test (1–2 months)
   Confirm the pathogenic gene and mutation site; perform genetic verification on both partners and necessary family members; design a personalized testing protocol and assess ADO risk. This step is the foundation of PGT-M and cannot be omitted.
2. Ovarian Stimulation and Egg Retrieval (2–3 weeks)
   Develop an ovulation induction plan based on the woman's age, AMH, and antral follicle count; perform IVF after egg retrieval.
3. Embryo Culture and Blastocyst Formation (5–6 days)
   Culture to the blastocyst stage; embryologists assess quality and select well-developed blastocysts for biopsy.
4. Trophectoderm Biopsy (1 day)
   Take 5–10 cells from the trophectoderm of the blastocyst; the procedure usually takes a few minutes. Embryos are cryopreserved after biopsy.
5. Genetic Testing and Analysis (2–4 weeks)
   Perform DNA amplification and sequencing on the biopsied cells; interpret results in conjunction with family pre-test data. The report should include quality control parameters and clear clinical recommendations.
6. Embryo Transfer (1 day)
   Select an embryo not carrying the pathogenic gene for frozen-thawed transfer. The transfer cycle requires endometrial preparation.
7. Prenatal Diagnosis Confirmation (After Pregnancy)
   After successful transfer, amniocentesis should be performed at 16–20 weeks of gestation to verify the fetal genotype. PGT-M results cannot replace prenatal diagnosis.

Q Frequently Asked Questions

Frequently Asked Questions: Eight Most Common Patient Concerns

Closing: Risk Reminder

Risk Reminder: PGT-M Must Be Conducted Within a Professional Framework

PGT-M is a serious reproductive genetic technology, not simply "choosing a healthy embryo." It involves complex genetic principles, technical limitations, ethical considerations, and medical decisions. Whether Thailand PGT-M is reliable ultimately depends on three core elements: whether adequate genetic preparation has been completed, whether a technically standardized institution has been selected, and whether the inherent limitations of the technology are understood and accepted.

As a reproductive doctor, it is recommended that patients at risk of monogenic diseases complete the following steps before making a decision: ① Seek professional consultation in the genetics department of a top-tier hospital to clarify the pathogenic site; ② Obtain detailed technical plans and laboratory qualification information from at least 2–3 Thai institutions; ③ Thoroughly discuss risks such as mosaicism, ADO, and result uncertainty with a genetic counselor; ④ Confirm the specific arrangements for prenatal diagnosis after transfer.

The results of PGT-M directly influence embryo selection decisions. Negligence at any stage can lead to irreversible consequences. Under the premise of technical standardization and full informed consent, Thailand PGT-M can be an effective tool for blocking the transmission of genetic diseases. Conversely, if information is not transparent or preparation is insufficient, it may lead to unreliable results, wasted cycles, or even misdiagnosis.